Immunotherapy Advances
@imtadvances.bsky.social
#OpenAccess journal covering the translational pipeline for #immunotherapy 🎯Included in WoS, PubMed & Scopus
A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs.
Read the open access article: https://bit.ly/3HnCGdN
Read the open access article: https://bit.ly/3HnCGdN
February 2, 2026 at 11:35 AM
A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs.
Read the open access article: https://bit.ly/3HnCGdN
Read the open access article: https://bit.ly/3HnCGdN
📢 Call for papers!
Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.
Deadline: March 2026.
Submit now: https://bit.ly/45mr1m8
Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.
Deadline: March 2026.
Submit now: https://bit.ly/45mr1m8
January 31, 2026 at 10:27 AM
📢 Call for papers!
Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.
Deadline: March 2026.
Submit now: https://bit.ly/45mr1m8
Immunotherapy Advances invites submissions for our Special Collection on Neuroimmunology and Immunotherapy, guest edited by Marianne Boes & Majid Ghareghanim.
Deadline: March 2026.
Submit now: https://bit.ly/45mr1m8
🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors.
Read the open access article: https://bit.ly/3Z8hDBW
##Immunotherapy #CellTherapy
Read the open access article: https://bit.ly/3Z8hDBW
##Immunotherapy #CellTherapy
January 30, 2026 at 4:39 PM
🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors.
Read the open access article: https://bit.ly/3Z8hDBW
##Immunotherapy #CellTherapy
Read the open access article: https://bit.ly/3Z8hDBW
##Immunotherapy #CellTherapy
✨ Our 2025 must‑read articles are now live!
Explore the most‑viewed and most‑cited immunotherapy papers from the past year
Discover them here: https://bit.ly/45ELeXc
##Immunotherapy
Explore the most‑viewed and most‑cited immunotherapy papers from the past year
Discover them here: https://bit.ly/45ELeXc
##Immunotherapy
January 29, 2026 at 2:45 PM
✨ Our 2025 must‑read articles are now live!
Explore the most‑viewed and most‑cited immunotherapy papers from the past year
Discover them here: https://bit.ly/45ELeXc
##Immunotherapy
Explore the most‑viewed and most‑cited immunotherapy papers from the past year
Discover them here: https://bit.ly/45ELeXc
##Immunotherapy
Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers.
This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.
📄 https://bit.ly/45vtfmp
This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.
📄 https://bit.ly/45vtfmp
January 15, 2026 at 11:30 AM
Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers.
This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.
📄 https://bit.ly/45vtfmp
This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.
📄 https://bit.ly/45vtfmp
Reposted by Immunotherapy Advances
Support @imtadvances.bsky.social in advancing immunotherapies for neurodegenerative & CNS immune-mediated diseases.
We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp
#ImmunoSky #Immunotherapy
We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp
#ImmunoSky #Immunotherapy
January 2, 2026 at 4:00 PM
Support @imtadvances.bsky.social in advancing immunotherapies for neurodegenerative & CNS immune-mediated diseases.
We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp
#ImmunoSky #Immunotherapy
We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp
#ImmunoSky #Immunotherapy
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.
Read here📄 https://bit.ly/4pw1rVL
Read here📄 https://bit.ly/4pw1rVL
January 13, 2026 at 12:00 PM
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.
Read here📄 https://bit.ly/4pw1rVL
Read here📄 https://bit.ly/4pw1rVL
🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection
Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.
Deadline: March 2026.
Learn more: https://bit.ly/4psT5hG
Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.
Deadline: March 2026.
Learn more: https://bit.ly/4psT5hG
January 9, 2026 at 12:30 PM
🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection
Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.
Deadline: March 2026.
Learn more: https://bit.ly/4psT5hG
Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.
Deadline: March 2026.
Learn more: https://bit.ly/4psT5hG
Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy.
This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.
📄 https://bit.ly/3SVZsMC
This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.
📄 https://bit.ly/3SVZsMC
January 7, 2026 at 3:08 PM
Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy.
This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.
📄 https://bit.ly/3SVZsMC
This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.
📄 https://bit.ly/3SVZsMC
Happy holidays from all of us! ❄️✨
Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!
Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!
December 24, 2025 at 1:09 PM
Happy holidays from all of us! ❄️✨
Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!
Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!
Natural killer cells are gaining momentum in cancer immunotherapy. This open-access review in Immunotherapy Advances explores how CAR-NK cells, NK engagers, cytokines and checkpoint inhibitors are being harnessed to boost anti-tumour immunity.
🔗 https://bit.ly/4j8dKEW
🔗 https://bit.ly/4j8dKEW
December 17, 2025 at 1:26 PM
Natural killer cells are gaining momentum in cancer immunotherapy. This open-access review in Immunotherapy Advances explores how CAR-NK cells, NK engagers, cytokines and checkpoint inhibitors are being harnessed to boost anti-tumour immunity.
🔗 https://bit.ly/4j8dKEW
🔗 https://bit.ly/4j8dKEW
🎧 ITA Wrapped!
A standout year for Immunotherapy Advances!
Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.
A standout year for Immunotherapy Advances!
Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.
December 10, 2025 at 5:41 PM
🎧 ITA Wrapped!
A standout year for Immunotherapy Advances!
Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.
A standout year for Immunotherapy Advances!
Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.
Congratulations to the winners of the BSI journals-sponsored Poster Prizes! 🎉
Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏
Full details here 👉 https://bit.ly/3MljD6r
Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏
Full details here 👉 https://bit.ly/3MljD6r
December 5, 2025 at 3:51 PM
Congratulations to the winners of the BSI journals-sponsored Poster Prizes! 🎉
Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏
Full details here 👉 https://bit.ly/3MljD6r
Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏
Full details here 👉 https://bit.ly/3MljD6r
Attending #BSI25?📣 Don’t miss AI in Publishing with Rachel Moriarty from our publisher OUP.
Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author.
🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C
##Immunology
Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author.
🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C
##Immunology
December 3, 2025 at 11:34 AM
Attending #BSI25?📣 Don’t miss AI in Publishing with Rachel Moriarty from our publisher OUP.
Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author.
🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C
##Immunology
Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author.
🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C
##Immunology
Read 'Knowledge-based immune-therapeutic advances for transplantation and cancer' by Elizabeth Simpson here: doi.org/10.1093/imma...
December 1, 2025 at 6:13 PM
Read 'Knowledge-based immune-therapeutic advances for transplantation and cancer' by Elizabeth Simpson here: doi.org/10.1093/imma...
Reposted by Immunotherapy Advances
Congratulations Liz! Read her historical perspective article in @imtadvances.bsky.social
December 1, 2025 at 5:49 PM
Congratulations Liz! Read her historical perspective article in @imtadvances.bsky.social
Reposted by Immunotherapy Advances
Since 1986, CD40’s role in #immunity has expanded. @imtadvances.bsky.social's upcoming collection will explore therapeutic targeting of CD40/CD154.
Submit your work to get involved: oxford.ly/3M5mYqo
#ImmunoSky #Immunotherapy
Submit your work to get involved: oxford.ly/3M5mYqo
#ImmunoSky #Immunotherapy
November 29, 2025 at 7:00 PM
Since 1986, CD40’s role in #immunity has expanded. @imtadvances.bsky.social's upcoming collection will explore therapeutic targeting of CD40/CD154.
Submit your work to get involved: oxford.ly/3M5mYqo
#ImmunoSky #Immunotherapy
Submit your work to get involved: oxford.ly/3M5mYqo
#ImmunoSky #Immunotherapy
🛡️ This #PublishingIntegrityWeek, BSI journals are tackling papermills, promoting AI transparency, DEI & accessibility, and supporting ethical research in immunology.
Read more 👉 https://bit.ly/4odyvAZ
Read more 👉 https://bit.ly/4odyvAZ
November 21, 2025 at 5:05 PM
🛡️ This #PublishingIntegrityWeek, BSI journals are tackling papermills, promoting AI transparency, DEI & accessibility, and supporting ethical research in immunology.
Read more 👉 https://bit.ly/4odyvAZ
Read more 👉 https://bit.ly/4odyvAZ
New review by Blee et al. “Turning the Tide: Harnessing Vaccines & Viruses to Fight Cancer” 🚀
How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk
##CancerResearch #Immunotherapy
How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk
##CancerResearch #Immunotherapy
November 21, 2025 at 9:46 AM
New review by Blee et al. “Turning the Tide: Harnessing Vaccines & Viruses to Fight Cancer” 🚀
How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk
##CancerResearch #Immunotherapy
How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk
##CancerResearch #Immunotherapy
🧬 Therapeutic cancer vaccines are back in focus! Advances in neo-antigen T cells, dendritic cell biology, and mRNA tech are paving the way for next-gen immunotherapy.
Read the Open Access review: https://bit.ly/4cefxGm
#CancerVaccines #Immunotherapy #mRNA #Oncology
Read the Open Access review: https://bit.ly/4cefxGm
#CancerVaccines #Immunotherapy #mRNA #Oncology
November 13, 2025 at 6:54 PM
🧬 Therapeutic cancer vaccines are back in focus! Advances in neo-antigen T cells, dendritic cell biology, and mRNA tech are paving the way for next-gen immunotherapy.
Read the Open Access review: https://bit.ly/4cefxGm
#CancerVaccines #Immunotherapy #mRNA #Oncology
Read the Open Access review: https://bit.ly/4cefxGm
#CancerVaccines #Immunotherapy #mRNA #Oncology
🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others.
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
November 7, 2025 at 11:10 AM
🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others.
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
👉 https://bit.ly/3T2blRg
##Immunotherapy #CancerImmunology
🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies.
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
November 6, 2025 at 10:40 AM
🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies.
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
👉 https://bit.ly/4ncWCzv
##Immunotherapy #CD8Tcells #CancerResearch
From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy.
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
October 22, 2025 at 3:30 PM
From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy.
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
🔓 Open access: https://bit.ly/4j8dKEW
#Immunotherapy #NKcells #CancerResearch
New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity.
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
October 18, 2025 at 10:13 AM
New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity.
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.
🔗 Open access: https://bit.ly/3J8pESs
#Immunology #Psoriasis
Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration.
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
October 17, 2025 at 10:23 AM
Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration.
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch
🔗 Open access: https://bit.ly/4ncWCzv
#Immunotherapy #CD8TCells #CancerResearch